{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Arnone AA"],"funding":["American Association for Cancer Research (AACR)","HHS | NIH | National Cancer Institute","DOD | USA | MEDCOM | Congressionally Directed Medical Research Programs (CDMRP)","V Foundation for Cancer Research (VFCR)","NCI NIH HHS","HHS | NIH | National Cancer Institute (NCI)","V Foundation for Cancer Research","DOD | USA | MEDCOM | Congressionally Directed Medical Research Programs","American Association for Cancer Research"],"pagination":["219-234"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11822015"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["17(2)"],"pubmed_abstract":["The gut microbiome, or the community of microorganisms residing in the gastrointestinal tract, has emerged as an important factor in breast cancer etiology and treatment. Specifically, the impact of gut bacterial populations on breast cancer therapeutic outcomes is an emerging area of research. The microbiota's role in modifying the pharmacokinetics of chemotherapy and endocrine-targeting therapies can alter drug efficacy and toxicity profiles. In addition, the gut microbiome's capacity to regulate systemic inflammation and immune responses may influence the effectiveness of both conventional and immunotherapeutic strategies for the treatment of breast cancer. Overall, while the bidirectional interactions between the gut microbiome and breast cancer therapies are still being studied, its i"],"journal":["EMBO molecular medicine"],"pubmed_title":["Gut microbiota interact with breast cancer therapeutics to modulate efficacy."],"pmcid":["PMC11822015"],"funding_grant_id":["BC210715","R01CA253329","U01 CA272541","R01 CA253329","24-40-12-ARNO","U01CA272541","BC230701","D2024-014"],"pubmed_authors":["Cook KL","Howard-McNatt M","Heeke AL","Arnone AA","Ansley K"],"additional_accession":[]},"is_claimable":false,"name":"Gut microbiota interact with breast cancer therapeutics to modulate efficacy.","description":"The gut microbiome, or the community of microorganisms residing in the gastrointestinal tract, has emerged as an important factor in breast cancer etiology and treatment. Specifically, the impact of gut bacterial populations on breast cancer therapeutic outcomes is an emerging area of research. The microbiota's role in modifying the pharmacokinetics of chemotherapy and endocrine-targeting therapies can alter drug efficacy and toxicity profiles. In addition, the gut microbiome's capacity to regulate systemic inflammation and immune responses may influence the effectiveness of both conventional and immunotherapeutic strategies for the treatment of breast cancer. Overall, while the bidirectional interactions between the gut microbiome and breast cancer therapies are still being studied, its i","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Feb","modification":"2026-06-02T20:02:24.113Z","creation":"2025-04-07T07:53:37.214Z"},"accession":"S-EPMC11822015","cross_references":{"pubmed":["39820166"],"doi":["10.1038/s44321-024-00185-0"]}}